{
  "first_published_at": "2012-08-20", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON180636", 
  "title": "Doripenem (Doribax▼): current dosing regimen is insufficient in some patients – updated dosing recommendations", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 104, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Doripenem (Doribax&#9660;): current dosing regimen is insufficient in some patients &#8211; updated dosing recommendations</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--The recommended dose of doripenem to treat nosocomial pneumonia in patients with augmented renal function and/or infections with pathogens with possible decreased susceptibility has been increased to 1 g every 8 hours given as a 4-hour infusion.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>The recommended dose of doripenem to treat nosocomial pneumonia in patients with augmented renal function and/or infections with pathogens with possible decreased susceptibility has been increased to 1 g every 8 hours given as a 4-hour infusion. Previous dosing regimens for doripenem in such patients were found to be insufficient.<br><br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Doripenem (Doribax&#9660;) is a carbapenem antibacterial agent indicated for nosocomial pneumonia (including ventilator&#8211;associated pneumonia), complicated intra-abdominal infections and complicated urinary tract infections.</p>\n\n<p>A recent review of study data on nosocomial pneumonia (including ventilator&#8211;associated pneumonia) indicates that the currently approved dose of doripenem is insufficient in patients with augmented renal function (particularly those with creatinine clearance (CrCl &#8805; 150 mL/min) and/or infections with pathogens with possible decreased susceptibility and should be increased.</p>\n\n<div class=\"dull_highlight\">\n<h3>Advice for healthcare professionals:</h3>\n\n<ul>\n<li>For patients with augmented renal function and/or infections with pathogens with possible decreased susceptibility, the recommended dose of doripenem to treat nosocomial pneumonia is now 1 g every 8 hours given as a 4-hour infusion</li>\n\n<li>Treatment duration of 10&#8211;14 days is usually required for patients with such infections and is often closer to 14 days for patients infected with pathogens such as <em>Pseudomonas </em>spp. and <em>Acinetobacter </em>spp.<br />\n</li>\n</ul>\n</div>\n\n<p>No changes to the recommended doripenem doses for treating nosocomial pneumonia (including ventilator-associated pneumonia) due to susceptible pathogens in patients with non-augmented renal clearance, or for treating complicated intra-abdominal infections and complicated urinary tract infections, are required.</p>\n\n<p>The new recommendations will be available in the updated <a target=\"_blank\" href=\"http://www.medicines.org.uk/EMC/medicine/21208/SPC/Doribax+500mg+powder+for+solution+for+infusion/]\">product information</a>. Information on the appropriate use of antibiotics and prevalence of resistance can be found in <a target=\"_blank\" href=\"http://www.nice.org.uk/#panel3\">NICE guidance</a></p>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"/home/groups/comms-ic/documents/websiteresources/con175479.pdf\">Letter to healthcare professionals sent in July 2012</a></p>\n\n<p>BNF section <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/201584.htm\">5.1: Antibacterial drugs</a></p>\n\n<p><em>Article citation: Drug Safety Update August 2012, vol 6, issue 1: A3</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Doripenem (Doribax&#9660;) is a carbapenem antibacterial agent indicated for nosocomial pneumonia (including ventilator&#8211;associated pneumonia), complicated intra-abdominal infections and complicated urinary tract infections.</p>\n\n<p>A recent review of study data on nosocomial pneumonia (including ventilator&#8211;associated pneumonia) indicates that the currently approved dose of doripenem is insufficient in patients with augmented renal function (particularly those with creatinine clearance (CrCl &#8805; 150 mL/min) and/or infections with pathogens with possible decreased susceptibility and should be increased.</p>\n\n<div class=\"dull_highlight\">\n<h3>Advice for healthcare professionals:</h3>\n\n<ul>\n<li>For patients with augmented renal function and/or infections with pathogens with possible decreased susceptibility, the recommended dose of doripenem to treat nosocomial pneumonia is now 1 g every 8 hours given as a 4-hour infusion</li>\n\n<li>Treatment duration of 10&#8211;14 days is usually required for patients with such infections and is often closer to 14 days for patients infected with pathogens such as <em>Pseudomonas </em>spp. and <em>Acinetobacter </em>spp.<br>\n</li>\n</ul>\n</div>\n\n<p>No changes to the recommended doripenem doses for treating nosocomial pneumonia (including ventilator-associated pneumonia) due to susceptible pathogens in patients with non-augmented renal clearance, or for treating complicated intra-abdominal infections and complicated urinary tract infections, are required.</p>\n\n<p>The new recommendations will be available in the updated <a target=\"_blank\" href=\"http://www.medicines.org.uk/EMC/medicine/21208/SPC/Doribax+500mg+powder+for+solution+for+infusion/%5D\">product information</a>. Information on the appropriate use of antibiotics and prevalence of resistance can be found in <a target=\"_blank\" href=\"http://www.nice.org.uk/#panel3\">NICE guidance</a></p>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con175479.pdf\">Letter to healthcare professionals sent in July 2012</a></p>\n\n<p>BNF section <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/201584.htm\">5.1: Antibacterial drugs</a></p>\n\n<p><em>Article citation: Drug Safety Update August 2012, vol 6, issue 1: A3</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-08-01", 
  "date_last_modified": "2013-01-28", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Letter to healthcare professionals sent in July 2012", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con175479.pdf", 
      "filename": "downloads/098155c50643f32788d6166d717270f78959dd61/con175479.pdf", 
      "original_filename": "con175479.pdf"
    }
  ], 
  "_item_id": 104, 
  "summary": "The recommended dose of doripenem to treat nosocomial pneumonia in patients with augmented renal function and/or infections with pathogens with possible decreased susceptibility has been increased to 1 g every 8 hours given as a 4-hour infusion. Previous dosing regimens for doripenem in such patients were found to be insufficient.", 
  "body": "Article date: August 2012\n\nDoripenem (Doribax▼) is a carbapenem antibacterial agent indicated for nosocomial pneumonia (including ventilator–associated pneumonia), complicated intra-abdominal infections and complicated urinary tract infections.\n\nA recent review of study data on nosocomial pneumonia (including ventilator–associated pneumonia) indicates that the currently approved dose of doripenem is insufficient in patients with augmented renal function (particularly those with creatinine clearance (CrCl ≥ 150 mL/min) and/or infections with pathogens with possible decreased susceptibility and should be increased.\n\n### Advice for healthcare professionals:  \n  \n  * For patients with augmented renal function and/or infections with pathogens with possible decreased susceptibility, the recommended dose of doripenem to treat nosocomial pneumonia is now 1 g every 8 hours given as a 4-hour infusion  \n  * Treatment duration of 10–14 days is usually required for patients with such infections and is often closer to 14 days for patients infected with pathogens such as Pseudomonas spp. and Acinetobacter spp.  \n  \n  \nNo changes to the recommended doripenem doses for treating nosocomial pneumonia (including ventilator-associated pneumonia) due to susceptible pathogens in patients with non-augmented renal clearance, or for treating complicated intra-abdominal infections and complicated urinary tract infections, are required.\n\nThe new recommendations will be available in the updated [product information](http://www.medicines.org.uk/EMC/medicine/21208/SPC/Doribax+500mg+powder+for+solution+for+infusion/%5D). Information on the appropriate use of antibiotics and prevalence of resistance can be found in [NICE guidance](http://www.nice.org.uk/#panel3)\n\nFurther information:\n\n[ASSET_TAG](#ASSET0)\n\nBNF section [5.1: Antibacterial drugs](http://www.medicinescomplete.com/mc/bnf/current/201584.htm)\n\nArticle citation: Drug Safety Update August 2012, vol 6, issue 1: A3\n"
}